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Introduction
Common agents currently used in treating metastatic
breast cancer are the antimitotics paclitaxel and docetaxel
[1,2]. These drugs bind to β-tubulin, a major protein in
mitotic spindles, and halt cell division at metaphase. Their
effectiveness in cancer chemotherapy is thought to be
due to their ability to reduce the dynamics of microtubules
in mitotic spindles, thus preventing spindle assembly and
interrupting the normal movement of sister chromatids
toward the spindle poles [3–9]. Tubulin, a 100kDa αβ
heterodimer, is structurally heterogeneous, with seven
genes encoding α-tubulin and β-tubulin isotypes. The
major differences between isotype classes reside in the
last 15–20 amino acids of the carboxy-termini [10,11],
BCIP = 5-bromo-4-chloroindol-3-yl phosphate; cDNA = complementary DNA; EGTA = (ethylene-bis[oxyethylenenitrilo])tetraacetic acid; CHTN =
Cooperative Human Tissue Network; ELISA = enzyme-linked immunosorbent assay; MAP = microtubule associated protein; MES = 2-(N-
morpholino)-ethane sulfonic acid; NBT = nitro blue tetrazolium; PBS = phosphate-buffered saline; PC-tubulin = MAP-free phosphocellulose-purified
tubulin; PCR = polymerase chain reaction; PIPES = piperazine-N,N′-bis(2-ethanesulfonic acid); PVDF = poly(vinylidene difluoride).
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Abstract
Background: Antimitotic chemotherapeutic agents target
tubulin, the major protein in mitotic spindles. Tubulin isotype
composition is thought to be both diagnostic of tumor
progression and a determinant of the cellular response to
chemotherapy. This implies that there is a difference in isotype
composition between normal and tumor tissues.
Methods: To determine whether such a difference occurs in
breast tissues, total tubulin was fractionated from lysates of
paired normal and tumor breast tissues, and the amounts of β-
tubulin classes I + IV, II, and III were measured by competitive
enzyme-linked immunosorbent assay (ELISA). Only primary
tumor tissues, before chemotherapy, were examined. Her2/neu
protein amplification occurs in about 30% of breast tumors and
is considered a marker for poor prognosis. To gain insight into
whether tubulin isotype levels might be correlated with
prognosis, ELISAs were used to quantify Her2/neu protein
levels in these tissues.
Results: β-Tubulin isotype distributions in normal and tumor
breast tissues were similar. The most abundant β-tubulin
isotypes in these tissues were β-tubulin classes II and I + IV.
Her2/neu levels in tumor tissues were 5–30-fold those in
normal tissues, although there was no correlation between the
Her2/neu biomarker and tubulin isotype levels.
Conclusion: These results suggest that tubulin isotype levels,
alone or in combination with Her2/neu protein levels, might not
be diagnostic of tumorigenesis in breast cancer. However, the
presence of a broad distribution of these tubulin isotypes (for
example, 40–75% β-tubulin class II) in breast tissue, in
conjunction with other factors, might still be relevant to disease
progression and cellular response to antimitotic drugs.
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and these differences have been exploited in the develop-
ment of isotype-specific antibodies [12–14]. Mammalian
microtubules are formed from a mixture of α-tubulin and
β-tubulin isotype classes [11,15,16], and the antimitotics
used in chemotherapy interact primarily with β-tubulin. In
vertebrates the concentrations of the specific isotypes
vary in different tissues [11,17], although the functional
role for the variability in tubulin polypeptides is uncertain
[17,18].
The expression of genes encoding α-tubulin and β-tubulin
seems to be developmentally regulated [19]. For example,
tubulin isotype expression patterns change during the
development and maturation of neurons [14,20]. Studies
with paclitaxel or other antimitotic agents, such as
colchicine or estramustine, indicate that drug interactions
with tubulin isotypes differ [21–25] and might contribute to
cell resistance to antimitotics [26–31]. However, one
group of antimitotic agents, the vinca alkaloids, was shown
to bind with similar affinity to all tubulin isotypes [12], sug-
gesting that alterations in drug binding affinity is unlikely to
be the cause of drug resistance. Furthermore, whereas
some of these data suggest a role for tubulin isotypes in
drug resistance, cell growth, and differentiation, other work
indicates that isotype-independent factors affecting micro-
tubule polymer formation are more important than changes
in isotype levels [32–35]. For example, a decrease in total
polymer concentrations causes resistance to microtubule-
stabilizing agents such as paclitaxel [34,35].
The work presented here quantitatively compares the
tubulin isotype levels in normal and tumor breast tissues.
We developed an indirect, competitive enzyme-linked
immunosorbent assay (ELISA) using antibodies specific
for β-tubulin classes II, III and I + IV that is sensitive to
1µg/ml tubulin. The results of the ELISA assay agree with
quantitative Western blotting and indicate that β-tubulin
class II predominates in both normal and tumor breast
tissues. Isotype levels are similar in both tissues, but sur-
prisingly they exhibit a broad fractional distribution. To
explore this further we measured Her2/neu protein levels,
which are known to be correlated with poor prognosis.
We demonstrate that although Her2/neu levels in tumor
tissues were 5–30-fold those in normal tissues, there was
no correlation between the Her2/neu biomarker and
tubulin isotype levels. Taken together, these data suggest
that, unlike previous reports on small cell lung cancer [36],
β-tubulin isotype levels are not diagnostic markers in
breast cancer. These results challenge the hypothesis of a
universal role for tubulin isotypes in tumor growth and the
development of drug resistance. Nevertheless, we cannot
exclude the possibility that changes in the distribution of
tubulin isotypes in normal and tumor breast tissue, in con-
junction with other molecular factors, might still be rele-
vant to disease progression and cellular response to
antimitotic drugs.
Materials and methods
Reagents
MgSO4, (ethylene-bis[oxyethylenenitrilo])tetraacetic acid
(EGTA), GTP (type II-S), glycerol, 2-(N-morpholino)-
ethane sulfonic acid (MES), Nonidet P 40, piperazine-
N,N′-bis(2-ethanesulfonic acid) (PIPES) and Triton X-100
were purchased from Sigma Chemical Company.
Sephadex G-50 was from Pharmacia. Nitro blue tetra-
zolium (NBT), 5-bromo-4-chloroindol-3-yl phosphate
(BCIP) and poly(vinylidene difluoride) (PVDF) were from
Bio-Rad. Deionized (Nanopure) water was used in all
experiments.
Purification of tubulin from pig brain
Phosphocellulose-purified tubulin (PC-tubulin) free of
microtubule-associated proteins (MAPs) was obtained by
warm/cold polymerization/depolymerization with the addi-
tion of a final phosphocellulose chromatography step to
separate tubulin from MAPs [37,38]. Tubulin concentra-
tions were determined spectrophotometrically, using
ε278=1.2L/(gcm) [39].
Cell culture and Her2/neu ELISAs
The breast cancer cell lines MCF-7 and HCC1954 were
obtained from American Type Culture Collection and
grown under the recommended conditions. MCF-7 cells
are known to have fewer than five copies of the Her2/neu
gene, whereas HCC1954 cells overexpress the protein
because of gene amplification [40,41]. Her2/neu protein
levels were determined with a Her2/neu ELISA kit (Onco-
gene) in accordance with the manufacturer’s instructions.
This ELISA kit was also used to determine Her2/neu
protein levels in tissue samples.
Tissue preparation and tubulin fractionation
Anonymous paired tumor (n=20) and normal (n=20)
breast tissue samples (0.25–1.0g), quick-frozen in liquid
nitrogen within 1hour of surgery, were provided by the
Cooperative Human Tissue Network (CHTN, National
Cancer Institute) (Table 1). Pathology reports were pro-
vided by CHTN for each tissue sample. Only primary
tumor samples were examined. Normal tissue was taken
from the same breast at a site distant from the tumor and
evaluated for the presence of tumor cells. The patients in
the study, ages ranging from 28 to 92 years, had not
received prior radiation or chemotherapy. The diagnosis of
each patient is shown in Table 1. Tissue samples were
homogenized in a Dounce homogenizer on ice in 1ml of
lysis buffer (25mM MES, 1mM MgSO4, 2mM EGTA,
0.1mM GTP, 0.1% Triton X-100 with a protease inhibitor
cocktail [Complete Protease Inhibitor Tablets; Boehringer
Mannheim]).
Membranes were removed by pelleting at 4°C in a micro-
centrifuge for 5 min. Membrane lipids remained at the top
of the sample and a tiny pellet was often also observed.R159
The pellet was not sufficiently large to allow the determina-
tion of protein levels with our assay. The total protein con-
centration in the supernatant (separated from the lipid
fraction) was determined with the Advanced Protein Assay
Reagent (Cytoskeleton Inc). The supernatant was then
loaded on a 2 ml arginine–Sepharose column equilibrated
with the MES buffer above without Triton X-100. The pro-
cedure for arginine–Sepharose purification of tubulin was
presented in detail by Lacey and Snowdon [42]. An
enriched tubulin fraction was collected in high-salt MES
buffer (2.5% ammonium sulphate) and equilibrated in
10mM Pipes, pH6.9, 2mM EGTA, 1mM MgSO4,
0.05mM GDP, 0.01% Triton X-100, using a spun column.
The tubulin fractions were used in the ELISA and/or
Western blotting experiments. The same procedure was
used to fractionate pig brain samples to quantify tubulin
isotypes by Western blotting.
To ensure that arginine–Sepharose chromatography did
not preferentially fractionate specific tubulin isotypes,
microtubule protein fractions from an early stage in purifi-
cation (tubulin plus MAPs) were examined by ELISAs and
Western blotting. There were no differences before and
after arginine–Sepharose fractionation in the percentages
of any of the β-tubulin isotypes tested in this study (data
not shown).
Quantitative Western blotting
The monoclonal antibodies used in the studies, TUJ1 (anti-
β-tubulin class III), 7H12 (anti-β-tubulin classes I + IV), and
7B9 (anti-β-tubulin class II), have been characterized previ-
ously [13,14] and are highly specific for their epitopes.
Sequential immunoaffinity columns were used to purify
β-tubulin classes II and III with their associated α-tubulins as
described previously [12]. Known amounts of PC-tubulin,
β-tubulin classes II and III, and pig brain samples (n=12)
from the cerebellum and right cerebrum were examined by
SDS–polyacrylamide-gel electrophoresis and transferred to
PVDF filters [43]. Alkaline phosphatase colorimetric reac-
tions (NBT and BCIP) were used to identify tubulin isotypes.
Triplicate blots for each sample were analyzed by densitom-
etry (Molecular Dynamics with ImageQuant Software). The
linearity of response was established by systematically
varying the amounts of known tubulin loaded into wells and
plotting these values against densitometry results by using
Origin 5.0 (Microcal). These comparisons allowed us to cal-
ibrate the amounts of β-tubulin classes I + IV, II, and III in
PC-tubulin and in pig brain samples (Table 2). The same
procedures were used to quantify β-tubulin in five tumor and
normal breast tissues for comparison with the ELISA
results.
Tubulin isotype ELISAs
Indirect, competitive ELISAs were used to quantify the
tubulin isotypes in tissue samples. The method is adapted
from standard protocols for indirect ELISAs [44]. The indi-
rect ELISA involves the titration of antibodies reacted with
tubulin in solution. A known amount of tubulin is mixed
with the unknown sample; the antibodies compete with a
known amount of tubulin bound to the plate. A secondary
antibody generates the signal used to quantify the
unknown protein. The amount of known protein can be
adjusted to optimize the sensitivity of the assay.
Optimal tubulin binding (75µg/ml, 50µl per well) to poly-
styrene microtiter plates (96 wells; Nalge NUNC Interna-
tional) was performed overnight at 4°C in a humid
environment. Plates were then washed three times with
Available online http://breast-cancer-research.com/content/5/5/R157
Table 1
Tumor and normal tissue samples
Sample Patient diagnosis
T1/N1 Phyllodes tumor
T2/N2 Infiltrating ductal carcinoma
T3/N3 Invasive poorly differentiated carcinoma
T4/N4 Infiltrating ductal carcinoma
T5/N5 Invasive ductal carcinoma
T6/N6 Intraductal and invasive ductal carcinoma
T7/N7 Invasive ductal carcinoma
T8/N8 Infiltrating adenocarcinoma
T9/N9 Infiltrating ductal carcinoma
T10/N10 Infiltrating ductal carcinoma
T11/N11 Infiltrating ductal carcinoma
T12/N12 Infiltrating lobular carcinoma
T13/N13 Metastatic adenocarcinoma
T14/N14 Infiltrating lobular carcinoma
T15/N15 Invasive ductal carcinoma
T16/N16 High-grade invasive carcinoma
T17/N17 Infiltrating ductal carcinoma
T18/N18 Infiltrating ductal carcinoma
T19/N19 Adenocarcinoma
T20/N20 Infiltrating ductal carcinoma
Tissue samples: T, tumor, N, normal.
Table 2
Tubulin isotypes in pig brain
Location β I + IV (%) β II (%) β III (%)
Cerebellum 17.7 ± 4.1 52.6 ± 8.3 28.5 ± 5.2
Right cerebrum 14.1 ± 2.9 53.5 ± 5.4  30.7 ± 4.5
PC-tubulin 18.1 ± 9.1 54.1 ± 7.2  27.8 ± 4.3phosphate-buffered saline (PBS) and blotted dry. The
average values in pig brain tissues for each isotype (53%
β class II, 17% β classes I + IV, and 29% β class III; deter-
mined as described above; Table 2) were used to con-
struct standard curves in the tubulin isotype ELISA assay.
Duplicate standard curves for each antibody were made
with PC-tubulin (final concentration 150µg/ml, 3% nonfat
dried milk in PBS). Duplicate unknown tissue samples
were prepared by combining them with known levels of
PC-tubulin (1:1), then mixing them 1:1 with antibody in
3% nonfat dried milk in PBS.
Antibodies (usually about 1mg/ml) against β-tubulin
classes I + IV (7H12), II (7B9), and III (TUJ1) were used at
optimal dilutions (ranging from 1:500 to 1:10000) deter-
mined empirically for each new stock of antibody. Serial
dilutions (50µl per well) were performed, varying only the
protein concentration and keeping the antibody and nonfat
dried milk concentrations constant. Plates were left at
22°C under mild humidity for 2hours on a shaker and then
washed four times with PBS and blotted dry before addi-
tion of the secondary horseradish peroxidase-conjugated
antibody (Sigma) in 3% nonfat dried milk in PBS. Sec-
ondary antibody concentrations were optimized for each
new stock. After 2hours at 22°C on a shaker, plates were
washed four times with PBS, blotted dry and reacted with
tetramethylbenzidine (50µl per well). The reaction was
stopped with 1M sulfuric acid, and plates were read at
450nm in a 96-well plate reader (TECAN, Research Trian-
gle Park, North Carolina).
Data were fitted by nonlinear least squares, using Fitall
(MTR software, Toronto, Canada) modified with an expo-
nential fitting function. This fitter globally fits the standard
curve and the sample data to extract the amplitude, the
exponential curvature, and the amount of tubulin isotype in
the breast tissue sample. Typical ELISA data are shown in
Fig.1. In developing the quantitative tubulin ELISA, either
microtubule protein from pig brain containing unknown
amounts of tubulin or a known amount of PC-tubulin was
used as the experimental sample. This permitted a determi-
nation of the accuracy of our quantification. The experiments
with microtubule protein resulted in isotype percentages
similar to those determined by quantitative Western blotting.
Isotype determinations with the experimental samples made
with known PC-tubulin were, within error, the same as the
expected quantities (data not shown).
The reliability of the tubulin ELISA is indicated by compari-
son with quantitative Western blotting of breast tissue
samples (Figs 2 and 3). Five paired anonymous normal
and anonymous tumor samples were obtained in 1–2g
quantities sufficient for quantitative Western blotting
(kindly provided by Dr Terry Hall, University of Mississippi
Medical Center, Jackson, Mississippi). There is no signifi-
cant difference between normal and tumor tissue distribu-
tions of tubulin isotypes. However, β-tubulin classes II and
I + IV fractions vary widely: 0.23–0.54 and 0.20–0.67,
respectively.  β-Tubulin class III values are relatively con-
stant, 0.20–0.27 (with the exception of one pair, 0.09 and
0.11 for tumor [T4] and normal [N4]; Fig.3). These wide
distributions for β-tubulin classes II and I + IV agree with
the ELISAs for the larger study of 40 additional samples
from CHTN presented here (0.41–0.76 and 0.10–0.46,
respectively). Note also that, unlike for breast tissues,
quantitative Western blot analyses of pig brain samples
demonstrate relatively constant tubulin isotype fractions
described above (Table 2). The values for each isotype in
pig brain are in reasonable agreement with the values pre-
viously reported (58%, 25%, and 13% for β-tubulin
classes II, III, and IV) [45], further establishing the validity
Breast Cancer Research    Vol 5 No 5 Dozier et al.
R160
Figure 1
A typical set of ELISA data, standard curve (filled squares) and sample
(open squares), are presented with the best fits of the data. The
duplicate standards and sample data are globally fitted to an
exponential function Aexp(ci+βi/τ), where ci is the concentration of
(PC-tubulin-derived) β-tubulin isotype in each dilution and βi is the
concentration of breast tissue β-tubulin isotype in each sample,
corrected for dilution. The sample data are then corrected for this
additional concentration of breast tissue isotype and plotted with the
standard curve and the best fit to demonstrate the goodness of fit. Fits
of these data resulted in the following concentrations for β-tubulin
classes: I + IV, 4.09 µg/ml; III, 2.27 µg/ml; II, 18.34 µg/ml. Triplicate
ELISA data for each tissue sample were fitted separately and then
averaged to give the final results and standard deviations (Fig. 5).of this approach. This result supports the accuracy and
the sensitivity of the quantitative Western blots and
ELISAs and demonstrates that the wide distribution
observed for β-tubulin classes II and I + IV in breast
tissues is not due to error in measurement.
Immunohistochemistry
Tissues were fixed in 10% buffered formalin containing
2% zinc sulfate to preserve antigenic sites, then embed-
ded in paraffin, and sectioned on a Zeiss rotary micro-
tome. Trypsin digestion was performed at 22°C for 15 min
and followed by a wash with soybean trypsin inhibitor. The
slides were de-paraffinized with a total of three incuba-
tions in xylene, rehydrated through a graded alcohol series
beginning with 100%, 95%, 70%, and 50% in PBS, and
treated with 0.3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity. The sections
were blocked in 5% powdered skimmed milk in PBS
(pH 7.4) and incubated overnight in a humid chamber at
4°C with primary monoclonal antibodies. The slides were
washed with four changes of PBS, and incubated with a
working dilution of biotin-labeled anti-mouse secondary
antibody and avidin–biotin–peroxidase complex (ABC).
The color was developed with 17mM 3′,3′-diaminobenzi-
dine, 40mM hydrogen peroxide in 0.5mM Tris-HCl buffer
(pH 5.0). The sections were counterstained with Gill’s
hematoxylin, dehydrated, and mounted. Negative controls
were performed by omission of the primary antibody, and
positive controls for tubulin isotypes were performed with
pig brain tissues.
Real-time polymerase chain reaction (PCR)
Real-time PCR was used to determine tubulin isotype
mRNA levels in selected breast tissues (Table 1: T1, N1,
T4, N4, T12, N12, T13, N13, T15, N15, T18, N18, N6,
and T14). All the other breast tissue samples were
required in their entirety for the ELISA and immunohisto-
chemistry experiments. The purpose of these real-time
PCR experiments was to establish whether tubulin protein
levels were correlated with mRNA levels. We developed
protocols for quantitative two-step reverse transcriptase
PCR to establish the relative amounts of mRNA tran-
scripts encoding each of the β-tubulin isotypes (classes I,
II, III, IVa, IVb, V, and VI). Total RNA was extracted from
5×10 6 cells with the Micro-to-Midi™ Total RNA Purifica-
tion System (Invitrogen). The purity of the RNA was
assessed by A260:A280 ratios. Electrophoresis with RNA
6000 LabChips™ and an Agilent 2100 Bioanalyzer was
used to determine the integrity of ribosomal RNA. The
RNA concentration was calculated from A260
(1 absorbance unit=40µg/ml) or obtained directly from
the bioanalyzer. Before the reverse transcription reaction,
genomic DNA contamination was eliminated by digestion
with deoxyribonuclease I (amplification grade; Sigma).
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Figure 2
Western blots of normal and tumor breast tissues after sample
enrichment for tubulin by arginine–Sepharose chromatography. For
quantitative Western blots the linearity of response for each antibody
was established for PC-tubulin. A linear response was also determined
for the antibody reaction with purified tubulin isotype samples. It was
not necessary to know total protein levels in these experiments,
because percentage isotypes were being quantified. (A) Immunoblot
with monoclonal antibody 7B9, specific for β-tubulin class II. Lane 1,
3.9 µg of PC-tubulin; lane 2, 0.35 µg of purified β-tubulin class II; lane
3, 30 µl of normal tissue sample, lane 4, 30 µl of tumor tissue sample.
(B) Immunoblot with monoclonal antibody TUJ1, specific for β-tubulin
class III. Lane 1, 3.9 µg of PC-tubulin; lane 2, 0.23 µg of purified
β-tubulin class III; lane 3, 30 µl of normal tissue sample; lane 4, 30 µl
of tumor tissue sample. (C) Immunoblot with monoclonal antibody
7H12, specific for β-tubulin classes I + IV. Lane 1, 3.9 µg of PC-
tubulin; lane 3, 30 µl of normal tissue sample; lane 4, 30 µl of tumor
tissue sample. Note that because β-tubulin classes I + IV constitute
only about 17% of the total tubulin in pig brain, we did not purify
sufficient quantities for controls on these Western blots. We
determined the quantity of β-tubulin classes I + IV by subtraction.
Figure 3
Bar graph showing the tubulin isotype distribution determined by
quantitative Western blotting in five paired normal and tumor breast
tissue samples. Bars: black, β-tubulin class II; dense hatch, β-tubulin
class III; sparse hatch, β-tubulin classes I + IV. Results are means and
SDs for duplicate blots.To minimize differences in efficiency of the reverse tran-
scription reaction, the various isotype complementary
DNAs (cDNAs) were produced in a single tube. Aliquots
were then used in quantitative PCR to determine the rela-
tive amount of each isotype cDNA independently. PCR
reactions were performed with isotype-specific primer
pairs for β-tubulin isotype classes I, II, III, IVa, and IVb as
described [46], with minor modifications to correct mis-
matches and to match the melting temperatures more
closely. Similar gene-specific primers were designed for
classes V and VI (Table 3). In preliminary experiments the
class II primers gave rise to two PCR products of approxi-
mately equal intensity, differing in size by 30 base pairs.
These two products were cloned into pCR-4, a TA-cloning
vector, and subsequently sequenced. The results showed
that the larger product was due to a tandem duplication at
the reverse primer. Thus, new primers for the β-tubulin
class II gene were designed. β-Tubulin cDNA was pro-
duced with gene-specific primers for each of the isotype
mRNAs and Reflectase reverse transcriptase (Active
Motif). Aliquots were used in quantitative real-time PCR to
determine independently the relative amount of each
isotype cDNA.
To obtain control cDNA template of a known quantity for
generation of standard curves, product from PCR reac-
tions was isolated from agarose gels with the
CONCERT™ Rapid Gel Extraction kit (Marligen). The con-
centration of purified cDNA was determined by analyzing
serial dilutions on DNA 500 LabChips (Agilent). Standard
curves for each β-tubulin isotype cDNA were generated
with real-time PCR at the same time as data were col-
lected for each of the tissue samples. With the use of trip-
licate samples and no template controls, real-time PCR
(iCycler™ iQ; Bio-Rad) with SYBR Green (Molecular
Probes) as the detection method was performed to quan-
tify the mRNA levels for selected breast tissues. The
amount of β-tubulin isotype mRNA in a known amount of
total RNA was determined from standard curves.
Results
Tubulin isotypes in breast tissues by
immunohistochemistry
A total of 20 anonymous paired normal and tumor tissue
samples were obtained from CHTN (Table 1). Selected
breast tissue samples (n=5) were examined by immuno-
histochemistry for the presence of tubulin isotypes. Thin
sections from all five samples (two normal and three
tumor) reacted moderately to strongly with monoclonal
antibodies against β-tubulin classes II and I + IV. Both cel-
lular and stromal staining were observed. Figure 4 shows
sections from a tumor sample that had relatively high
levels of β-tubulin class III levels by ELISA (Fig.5C: T18).
Some staining with antibody against β-tubulin class III was
also observed, mostly as diffuse background stromal
tissue staining (Fig.4C), although occasionally more spe-
cific reactivity occurred. A previous examination of five
normal and tumor breast tissues showed similar staining
patterns [47]. In that study, antibodies against β-tubulin
classes II and I + IV also reacted moderately to strongly
with cells, whereas β-tubulin class III was found in stromal
cells and rarely in punctate, irregular staining patterns,
suggesting cross sections of nerve fibers. β-Tubulin
class III in normal tissues is a highly specific marker for
neurons [10,19] and we therefore attribute most of the
β-tubulin class III antibody reactivity in the breast tissues
Breast Cancer Research    Vol 5 No 5 Dozier et al.
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Table 3
Primers for RT-PCR
Amplicon length
β-Tubulin gene Description Sequence (5′→3′) Tm (°C) (base pairs)
Class I Forward CCCCATACATACCTTGAGGCGA 59.8 289
Reverse GCCAAAAGGACCTGAGCGAA 59.1
Class II Forward ACGGGTTAGGGAAAGCGGA 59.6 241
Reverse TTCCGACACAAACGTTTATGTGA 56.7
Class III Forward ATGCGGGAGATCGTGCACAT 60.6 238
Reverse CCCCTGAGCGGACACTGT 60.0
Class IVa Forward TCTCCGCCGCATCTTCCA 59.8 272
Reverse GCTCTGGGGACATAATTTCCTCCT 60.0
Class IVb Forward GCTGTTTGTCTACTTCCTCCTGCT 60.4 344
Reverse CAGTTGTTCCCAGCACCACTCT 60.8
Class V Forward CGGGGAGGAAGCTTTTGAGGAT 60.5 244
Reverse CTGGGTAGAACCCGCAATTCTCT 60.2
Class VI Forward AGTTGTGTTGGGCTCACACCA 60.8 133
Reverse TTGCCACACTGGCCAATCTGA 60.9
Tm values were calculated for reaction conditions containing 50 mM NaCl.to the weak stromal reactivity and presence of nerve
fibers.
Quantification of tubulin isotypes in breast tissues by
ELISA
To quantify tubulin isotypes in breast tissue samples
(0.25–1.0g) we developed a sensitive and reliable indirect
ELISA (sensitive to levels of 1 µg/ml tubulin isotype)
(Fig.1). The sensitivity of the ELISA assay was verified by
quantitative Western blotting (Figs 2 and 3). These results
suggested that β-tubulin classes II and I + IV are the pre-
dominant tubulin isotypes in these tissues. This was veri-
fied by immunohistochemistry (Fig.4), which demonstrated
strong, specific staining by the antibodies against β-
tubulin classes II and I + IV. In the work presented here,
each tissue sample was examined in duplicate on
microtiter plates, and triplicate plates were measured to
obtain means and standard deviations for each isotype
(Fig.5). There was no difference in tubulin isotype levels in
normal and tumor tissues. The predominant isotype frac-
tion was β-tubulin class II (0.58±0.09 of the total). Both
β-tubulin classes III and I + IV were expressed in smaller
amounts in all tissues (0.17±0.08 and 0.26±0.08,
respectively). Figures 5A and 5B show β-tubulin classes I
+ IV and II plotted as a percentage of total tubulin (exclud-
ing β-tubulin class III, as discussed above), showing that in
each tissue sample β-tubulin class II predominated.
Figure 5C shows the distribution of β-tubulin class III.
Several samples had relatively high levels of β-tubulin
class III. Two of these, N16 and T18, were examined by
immunohistochemistry to determine whether the high level
of β-tubulin class III might be due to upregulation of this
isotype in tumor or normal cells; however, as discussed
above, only stromal staining was observed.
The fraction of β-tubulin class II in tissues varied from 0.41
to 0.76 (Fig.6). Figure 6A shows the similar distributions
of  β-tubulin class II in both normal and tumor tissues.
Figure 6B indicates the relative frequencies of fractions of
β-tubulin class II, demonstrating a Gaussian distribution
for the tissue samples. Student t-tests comparing normal
and tumor tissue samples showed no difference in mean
fraction of β-tubulin class II (0.60±0.10 and 0.56±0.07
for tumor and normal tissues, t=–1.454 and P=0.15).
(Student t-tests for tumor versus normal β-tubulin classes
III or I + IV also showed no significant difference:
t=0.776, P=0.44; and t=0.741, P=0.46.) The varying
amounts of isotypes in these tissue samples suggest that
isotype levels might be correlated with other biomarkers of
poor prognosis.
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Figure 4
Immunostaining of tumor tissue samples (T18). Thin sections of
paraffin-embedded tissue reacted with monoclonal antibody 7H12,
which recognizes β-tubulin classes I + IV (A); monoclonal antibody
7B9, which recognizes β-tubulin class II (B); and monoclonal antibody
TUJ1, which recognizes β-tubulin class III (C). (D) No primary antibody.
In these panels red staining indicates a positive reaction, and blue
staining indicates no reactivity. Note that (C) showed no reactivity with
tumor cells, only with background stromal tissue.
Figure 5
Bar graph showing quantification of β-tubulin classes I + IV (A), II (B),
and III (C) by ELISA. Tumor and normal samples are designated T or N
as defined in Table 1. Results are means and SDs determined from
three ELISAs for each tissue sample. The means for β-tubulin classes 
I + IV and II were calculated without the contribution from β class III
tubulin, which is known to be neuron-specific and was shown by
immunohistochemistry on these tissues to be due to the presence of
nerve fibers.Correlation of β β-tubulin isotype protein and mRNA
levels
To establish whether β-tubulin isotype protein levels could
be inferred from mRNA levels, we used quantitative real-
time PCR to measure β-tubulin mRNA levels in selected
breast tissues (Table 1: T1, N1, T4, N4, T12, N12, T13,
N13, T15, N15, T18, N18, N6, and T14) (Fig.7). These
data show a broad distribution of mRNA content for all
seven β-tubulin isotype classes. The lowest levels were
found for β-tubulin classes IVa and VI. The ranges of
tubulin levels for the other five isotype classes were
similar. Although differences between matched tumor and
normal tissues were found, there were no correlations
suggesting the upregulation or downregulation of specific
tubulin isotypes in tumor tissues compared with normal
(data not shown). When the fraction of mRNA for β-tubulin
classes I + IV, II, and III were plotted against the corre-
sponding fraction of protein, it became evident that there
is no correlation between tubulin mRNA and protein levels
in these tissues (Fig.8).
Comparison of Her2/neu and β β-tubulin class II expression
In an attempt to understand the significance of the distrib-
utions of β-tubulin classes II and I + IV in normal and tumor
breast tissues, we used ELISAs to quantify the Her2/neu
protein levels in these tissues. Expression of Her2/neu is
amplified in 30% of all breast tumors and data suggest
that it might be a negative prognostic indicator [48].
Figure 9A shows the levels of Her2/neu protein normal-
ized for total protein in tumor and normal tissues. Higher
Her2/neu levels were found in all tumor tissues compared
with normal tissues. This result verifies the pathology
reports (Table 1) that describe the tumor samples as
tumors. Note that one ‘normal’ tissue, N12, was shown to
have relatively high levels of Her2/neu protein. However,
an independent pathology report on this tissue sample
indicated a significant number of tumor cells throughout
the entire breast tissue, even though the ‘normal’ sample
was excised at a site distant from the tumor.
The increase of Her2/neu protein in tumor tissues com-
pared with normal tissues is shown in Fig.9B to be from
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Figure 6
Distribution of β-tubulin class II in tumor and normal tissue samples.
(A) Fractions of β-tubulin class II ranked in descending order. Tumor
and normal samples are designated as in Table 1. The fraction of
β-tubulin class II was calculated as the proportion of the total tubulin,
including β-tubulin classes I + IV and III. The distribution was similar
when β-tubulin class III was not included (data not shown). (B)
Frequency distribution for all data in (A). Gaussian fits of the data are
superimposed: solid line, all data; broken line, normal tissue; dotted
line, tumor tissue. The mean fraction of β-tubulin class II in tumor
tissues is 0.60 ± 0.10 and for normal tissue it is 0.56 ± 0.07. Student
t-test comparing the normal and tumor tissue data showed no
significant difference (t = –1.45429, P = 0.15).
Figure 7
Plot of the quantity of mRNA in selected breast tissues (Table 1: T1,
N1, T4, N4, T12, N12, T13, N13, T15, N15, T18, N18, N6, and T14)
for each β-tubulin isotype class (I, II, III, IVa, IVb, V, and VI). The data
are plotted as log attomoles of normalized cDNA to the total RNA
concentration in the sample. Open symbols, normal tissue; filled
symbols, tumor tissue.5-fold to more than 30-fold. The inset in Fig.9A compares
Her2/neu protein levels in a breast cancer cell line that
overexpresses Her2/neu with one that does not. The
increase in the Her2/neu overexpressing cells is more
than 40-fold. We infer from these data that the breast
tumor tissues approaching this level of Her2/neu expres-
sion would have significantly increased Her2/neu levels.
Plots of Her2/neu protein (Fig.10A) or fold increase in
Her2/neu protein (Fig.10B) against β-tubulin class II frac-
tion demonstrate no significant correlation. There is there-
fore no relationship between tubulin isotype levels and
Her2/neu protein expression.
Discussion
β β-Tubulin class II predominates in breast tissues
This is the first quantitative comparison of tubulin isotype
protein levels in human tissues. Previous work has indi-
cated that vertebrate tissues vary in their tubulin isotype
composition.  β-Tubulin class II predominates in brain
tissues and has been found in smaller amounts in other
tissues [19,45]. Classes III and IVa are primarily found in
neurons, whereas classes I and IVb are found in many
tissues [10,19]. β-Tubulin class V is present in small
amounts in many cell types [11] and class VI is found in
blood cells and hematopoietic tissues [49,50]. Much of
this quantitative work was done by comparing mRNA
levels. However, mRNA and protein levels are not corre-
lated for many human and yeast proteins, especially those
that are regulated by post-transcriptional processes
[51–53], although there is controversy regarding correct
statistical analysis and interpretation of some of these data
[54]. Intracellular tubulin levels are under both transcrip-
tional and post-transcriptional control. Fine-tuning of
tubulin levels during the cell cycle occurs by autoregula-
tion. This process alters mRNA stability and requires both
an essential sequence on polysomal β-tubulin mRNA and
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Figure 8
Correlation of β-tubulin isotype protein and mRNA levels for β-tubulin
classes I + IV, II, and III. In these calculations total tubulin was
determined by summation of β-tubulin isotype classes I + IV, II, and III.
The fraction of each isotype was determined relative to this total. 
(A) β-Tubulin class III; (B) β-tubulin class II; (C) β-tubulin classes I + IV.
Figure 9
Bar graph of Her2/neu protein in tissue samples quantified by ELISA.
(A) Her2/neu normalized for total protein for each tissue sample
tested. Sufficient quantities of only 32 of the 40 tissue samples were
available for testing. Error bars show SDs for duplicate ELISA plates.
The inset compares the total amount of Her2/neu protein in two breast
cancer cell lines: MCF-7 cells, which have fewer than five copies of the
Her2/neu gene, and HCC1954 cells, which overexpress the Her2/neu
protein. Overexpression in this cell line leads to a 40-fold increase in
Her2/neu protein level relative to that in MCF-7 cells. (B) Relative
amounts of Her2/neu protein in tumor tissue compared with the paired
normal tissue, showing the fold increase in Her2/neu for tumor tissues
ranging from about 5-fold to more than 30-fold.an amino-terminal Met-Arg-Glu-Ile sequence on the
nascent tubulin polypeptide [55–57]. Furthermore, α-
tubulin mRNA levels remain high even when protein syn-
thesis is repressed [58]. In fact, α-tubulin synthesis in
CHO cells seems to have a role in regulating β-tubulin
protein levels.
This phenomenon of tubulin post-transcriptional autoregu-
lation was demonstrated in a wide variety of vertebrate
and invertebrate cell types. It suggests that individual
tubulin isotype protein levels are all similarly regulated,
although this has not been demonstrated. Because the
total amount of intracellular tubulin depends on both
mRNA stability and protein half-life, these data together
indicate that high levels of tubulin mRNA might be associ-
ated with low levels of free tubulin subunits. This is sup-
ported by the recent mass spectrometry and isoelectric
focusing work that demonstrated a lack of correlation
between tubulin isotype protein levels and mRNA levels in
paclitaxel-resistant cell lines [59]. However, tubulin mRNA
levels are currently interpreted by most investigators as
directly representing the total intracellular tubulin protein
pool. One alternative to mRNA quantification is immuno-
staining. Although immunostaining of cells is useful for
localizing proteins in tissues and cells, accurate quantifica-
tion by this method is difficult [41]. Nevertheless, quantita-
tive measurement of protein levels is crucial for
understanding intracellular events. In our studies, quantita-
tive real-time PCR data from selected breast tissue
samples revealed that β-tubulin mRNA and protein levels
are not correlated. These results indicate that quantitative
studies of β-tubulin isotypes that are done exclusively with
PCR techniques should be interpreted with caution
because functional protein levels cannot be inferred.
Consistent with our results is the finding of both β-tubulin
classes I and II by immunostaining in many human tissues
and cell types [60]. To understand the relationship
between the drug target levels and the development of
drug resistance, it is essential to know the actual protein
amounts in tissues and cells. We demonstrate here by a
quantitative ELISA assay that the β-tubulin class II protein
is on average the most abundant isotype in human breast
tissues. We found a distribution of β-tubulin class II levels,
ranging from 0.41 to 0.76. This wide distribution was not
expected, because our study of tubulin isotypes in pig
brains showed very little brain-to-brain variation. To evalu-
ate the significance of the distribution of β-tubulin classes
II and I + IV in breast tissues, we measured the tissue
levels of Her2/neu protein, known to be amplified in 30%
of all breast tumors and associated with poor prognosis
[48]. All tumor tissues expressed higher levels of
Her2/neu relative to normal tissues. However, there was
no correlation between this biomarker and levels of
β-tubulin classes II or I + IV isotype levels. Thus the signifi-
cance of the range of isotype levels in breast tissues
remains unknown. Although it is possible that β-tubulin
class II levels might be correlated with a prognostic bio-
marker not yet examined [61], these results suggest that a
normal patient-to-patient variation might exist.
The ELISA method described here involves total extraction
of tubulin and does not differentiate between polymeriz-
able and nonpolymerizable tubulin fractions. There are
reports of tubulin isotypes that are differentially incorpo-
rated into microtubule structures [62]. However, it is not
possible to fractionate microtubules from total cytoplasmic
tubulin with quick-frozen human tissue samples. Current
experiments are exploring this aspect of tubulin isotype uti-
lization in cell culture studies. One complexity in our work
is the sampling of breast tissue. It is possible that samples
are composed of different amounts of heterogeneous cell
types. However, because our data show similar isotype
amounts in normal and tumor breast tissues, differential
tissue sampling seems not to be an issue in these experi-
ments. Our method is based in part on an ELISA assay
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Figure 10
Scatter plots showing the relationship of β-tubulin class II to Her2/neu
protein for each tissue sample. (A) The normalized Her2/neu protein
from Fig. 9A plotted against β-tubulin class II. (B) The fold increase in
Her2/neu from Fig. 9B plotted against β-tubulin class II. The line
represents a least-squares linear fit of the data, demonstrating no
correlation (r = –0.193, P = 0.491).developed by Thrower and colleagues [63] for tubulin
extracts. This work fulfills their suggestion to quantify
changes in tubulin isotype levels with the appropriate anti-
bodies, and establishes a sensitive and accurate assay to
complement mRNA assays and studies of the response of
cultured cells to antimitotic drugs.
The patient diagnoses for these tumor samples were most
commonly infiltrating ductal carcinoma (12 of 20 samples).
We found no correlations between tubulin isotype levels
and any of the variables given in the pathology reports
(estrogen receptor, progesterone receptor, age, race, or
histology grade). It should be noted that the ‘normal’
breast tissues examined in this study were excised from a
site distal to the tumor site but in the same breast. Histo-
logical examination of the ‘normal’ tissues indicates the
presence of fibrocystic changes in many of the samples
and therefore, although these changes are not uncommon
in normal aging, they cannot be classified as truly ‘normal’
breast tissue. However, independent pathology reports
determined that the ‘normal’ tissues were ‘non-tumor’
tissues with the exception of N1, N12, and N13, in which
tumor cells were noted. N1 and N13 were estimated to
contain more than 5% tumor cells. N12, however, had
tumor cells throughout the breast tissue and therefore
although the ‘normal’ sample was taken distal to the tumor
it contained significant numbers of tumor cells. N12 was
also shown in our ELISA studies to have relatively high
levels of Her2/neu protein. Thus, the Her2/neu ELISAs
provided a second means of grossly differentiating
between ‘tumor’ and ‘normal’ tissues for these patients.
It is important to note that many tumor tissues do not
express Her2/neu; it is therefore not a generally useful
marker for differentiating between tumor and normal
tissues. In addition, our work demonstrates that although
β-tubulin class III is a marker for aggressive neuroen-
docrine tumors [36,64], it is not a significant biomarker in
breast tumors. We speculate that this is because breast
tissue rarely dysregulates to neuroendocrine cell types.
Tumor and normal breast tissues have similar tubulin
isotype levels
Over the past decade paclitaxel and docetaxel have
become important chemotherapeutic agents for both
ovarian and breast cancers [1,2]. Considerable interest
has focused on the target receptor — tubulin — and mech-
anisms underlying efficacy, toxicity, and drug resistance
[7,8,23,24,27,28]. Whether tubulin isotype levels might
determine cellular responses to antimitotic agents remains
controversial. For example, paclitaxel-resistant lung cancer
cells and ovarian tumors were shown to have increased
levels of tubulin isotypes, particularly β-tubulin classes III
and IVa [28]. Furthermore, when paclitaxel-resistant lung
cancer cells were treated with antisense oligonucleotides
for  β-tubulin class III, the drug resistance was partly
reversed, coincident with decreased protein levels of
β-tubulin class III [65]. However, it should be noted that
β-tubulin classes I, II, III, and IVa all increased significantly
in paclitaxel-resistant lung cancer cells, indicating that the
drug effect did not uniquely involve a single tubulin
isotype. In other work, β-tubulin classes III and IVa were
shown to increase in paclitaxel-resistant prostate cancer
cells [29]. However, these two isotypes continued to be
expressed in the lowest amounts.
In ovarian cancer cells, mutations in residues near the
putative paclitaxel-binding site of β-tubulin class I were
found in paclitaxel-resistant ovarian cancer cells [23].
Other work suggests that changes in tubulin isotypes
alone cannot confer resistance to antimitotics. It was
demonstrated that one group of antimitotic agents, vinca
alkaloids, bind with similar affinity to all β-tubulin isotypes
[12], thus suggesting for therapy with vinorelbine, vinblas-
tine, or vincristine that tubulin isotype levels are incidental
for efficacy. Furthermore, transfection of CHO cells with
β-tubulin classes I, II, or IVb did not produce resistance to
paclitaxel [32]. The alternative hypothesis, derived from
the work of Cabral and colleagues, is that rather than the
tubulin isotype levels, the amount of polymerized tubulin is
the critical factor that regulates response to antimitotic
drugs. For example, total amounts of polymerizable tubulin
are decreased in paclitaxel-resistant cells, whereas col-
cemid-resistant tubulin or vinca alkaloid-resistant cells
have increased levels of assembled tubulin [34,66,67].
Furthermore, when cells were transfected with β-tubulin
class III, weak resistance to paclitaxel was found, and this
resistance was associated with decreased microtubule
stability [68]. This is consistent with the different modes of
action of these drugs: paclitaxel stabilizes microtubules
and colcemid inhibits tubulin assembly. In support of this
hypothesis, tubulin mutations consistent with altered
assembly properties have been identified in paclitaxel-
resistant and vinca alkaloid-resistant cells [33,66,69].
Conclusion
We demonstrate that normal and tumor breast tissues,
before chemotherapy or radiation treatment, have broad
distributions of β-tubulin isotypes. Furthermore, β class II
tubulin predominates in most breast tissues. The β-tubulin
isotype levels in normal and tumor tissue are not signifi-
cantly different and are therefore unlikely to contribute to
differential responses of tumors to antimitotic agents. The
initial drug sensitivity might depend upon the levels of
polymerized tubulin in normal versus tumor tissues associ-
ated with the differential expression of MAPs and dynam-
ics regulators such as stathmin [70], a hypothesis
currently being explored in our laboratory. The work pre-
sented here describes untreated tumors and should be
useful for comparison with paclitaxel-treated tumors as a
basis for evaluating tubulin isotype levels in response to
therapy or in the development of drug resistance.
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